Tumor Suppressor Gene *VHL*, Mechanism and Related Therapy

Dongrui Shi

Abstract

Von Hippel-Lindau (VHL) syndrome is a rare hereditary disorder characterized by the development of multiple tumors in various organs. This paper provides a comprehensive overview of the VHL gene, its mechanism of action, and its implications in VHL-related tumorigenesis. The first section explores the role of the VHL tumor suppressor gene in regulating angiogenesis and oxygen sensing, highlighting its significance in tumor suppression. The second section discusses the association between VHL gene mutations and the development of various tumor types, emphasizing the diverse clinical manifestations of VHL syndrome. The third section examines the diagnostic methods for identifying VHL gene mutations, including genetic testing and clinical evaluations. The fourth section delves into therapeutic approaches for managing VHL-related tumors, encompassing surgical interventions, targeted therapies, radiotherapy, and emerging treatment strategies. This paper aims to enhance understanding of VHL syndrome, facilitate early diagnosis, and guide treatment decisions for individuals affected by this complex disorder.

Keywords: Von Hippel-Lindau syndrome, VHL gene, tumor suppressor gene, tumorigenesis, angiogenesis, oxygen sensing, VHL-related tumors, VHL gene mutations, targeted therapies, surgical interventions, radiotherapy

Introduction

Cancer is a complex and devastating disease that arises due to the accumulation of genetic alterations in cells, leading to uncontrolled proliferation and tumor formation. Genetic mutations can disrupt the normal functioning of genes involved in critical cellular processes, including those that regulate cell division, growth, and programmed cell death. Tumor suppressor genes play a crucial role in preventing the development and progression of cancer by maintaining genomic stability and inhibiting tumor formation. One prominent tumor suppressor gene is the Von Hippel-Lindau (VHL) gene, named after the familial cancer syndrome associated with its mutations. The VHL gene is located on chromosome 3p25-26 and encodes for a protein called pVHL (Von Hippel-Lindau tumor suppressor protein). The loss or inactivation of VHL gene function has been implicated in the development of various types of tumors, including renal cell carcinoma (RCC), central nervous system hemangioblastomas, pheochromocytomas, and pancreatic neuroendocrine tumors.

The VHL gene exerts its tumor suppressor function through its involvement in multiple cellular processes. One of the key mechanisms by which the VHL gene functions is by regulating the stability of hypoxia-inducible factors (HIFs). HIFs are transcription factors that orchestrate the cellular response to low oxygen levels (hypoxia) by inducing the expression of genes involved in angiogenesis, glucose metabolism, and erythropoiesis. In normoxic conditions, pVHL targets HIFs for degradation via the ubiquitin-proteasome pathway, preventing their accumulation and downstream effects. However, in the absence or inactivation of pVHL, HIFs accumulate, leading to the dysregulation of HIF-dependent pathways and contributing to tumor development and progression.

The diagnosis of VHL syndrome and VHL gene mutations relies on genetic testing and screening methods. Genetic testing can identify germline VHL mutations, aiding in the early detection and management of VHL-related tumors. Clinical manifestations of VHL syndrome include various symptoms depending on the affected organs, such as retinal angiomas, central nervous system hemangioblastomas, and adrenal gland tumors. Regular surveillance and monitoring are crucial to detect and manage VHL-related tumors at an early stage, improving patient outcomes. Therapeutic approaches for VHL-related tumors primarily involve surgical interventions and targeted therapies. Surgical resection is the mainstay for the management of VHL-associated tumors, especially for localized lesions. However, due to the high recurrence rate and multifocal nature of some VHL-related tumors, additional treatment modalities are often necessary.

Targeted therapies have emerged as promising options for VHL-related tumors. Anti-angiogenic agents, such as vascular endothelial growth factor receptor (VEGFR) inhibitors, have shown efficacy in treating VHL-associated RCC and hemangioblastomas. These drugs disrupt the formation of new blood vessels, inhibiting tumor growth

and reducing the vascularization of lesions. Additionally, inhibitors targeting HIFs or their downstream pathways, such as mTOR inhibitors, have been investigated as potential therapeutics for VHL-related tumors. By suppressing the aberrant HIF signaling that occurs in the absence of functional pVHL, these agents aim to impede tumor growth and progression. Gene therapy approaches hold promise in the treatment of VHL-related tumors. Strategies involving the restoration of functional VHL gene expression or the delivery of therapeutic genes to compensate for VHL deficiency are being explored. Gene editing technologies, such as CRISPR-Cas9, offer the potential to correct VHL gene mutations directly in affected cells, restoring the tumor suppressor function of pVHL.

Despite the significant progress made in the field of VHL research, challenges remain. The heterogeneity of VHL-related tumors, their variable clinical manifestations, and the limited understanding of the underlying molecular mechanisms pose obstacles to the development of targeted therapies. Additionally, the management of VHL syndrome requires a multidisciplinary approach involving specialists from various medical disciplines, including genetics, oncology, neurology, and urology. Even, the Von Hippel-Lindau tumor suppressor gene (VHL) plays a critical role in preventing tumor development and progression. Its involvement in regulating hypoxia-inducible factors, angiogenesis, cell cycle progression, and apoptosis underscores its significance in cellular homeostasis and tumor suppression. VHL gene mutations contribute to the development of VHL syndrome and various associated tumors. Diagnostic methods, such as genetic testing and clinical surveillance, aid in the early detection and management of VHL-related tumors. Surgical interventions, targeted therapies, and gene therapy approaches offer treatment options for VHL-associated tumors, with ongoing research and clinical trials paving the way for future advancements. Understanding the mechanisms underlying VHL gene function and developing effective therapies for VHL-related tumors hold immense potential for improving patient outcomes and advancing cancer treatment strategies

Mechanism of VHL Tumor Suppressor Gene

The Von Hippel-Lindau (VHL) tumor suppressor gene plays a crucial role in maintaining cellular homeostasis and preventing the development of tumors. The mechanism by which the VHL gene exerts its tumor suppressor function involves the regulation of hypoxia-inducible factors (HIFs), control of angiogenesis and vascularization, impact on cell cycle progression and apoptosis, and interaction with other cellular pathways. One of the key functions of the VHL gene is its involvement in the regulation of HIF stability. HIFs are transcription factors that play a central role in the cellular response to low oxygen levels (hypoxia). Under normoxic conditions, prolyl hydroxylases (PHDs) hydroxylate specific proline residues on the alpha subunit of HIF, leading to its recognition by the VHL protein complex. This recognition triggers the ubiquitination and subsequent proteasomal degradation of HIF, preventing its accumulation and transcriptional activity. The VHL gene, therefore, acts as a negative regulator of HIF, maintaining HIF levels in check in the presence of adequate oxygen supply. In the absence or inactivation of the VHL gene, HIFs are no longer targeted for degradation, resulting in their stabilization and transcriptional activation. HIFs can then translocate to the nucleus and bind to hypoxia response elements (HREs) in the promoters of target genes, initiating the expression of genes involved in angiogenesis, glucose metabolism, and erythropoiesis. These HIF-dependent pathways promote tumor growth, angiogenesis, and survival under hypoxic conditions, facilitating the development and progression of tumors.

The VHL gene also plays a critical role in the regulation of angiogenesis, the formation of new blood vessels. The VHL protein complex interacts with various factors involved in vascularization, including vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). The binding of pVHL to these factors targets them for degradation, preventing excessive angiogenesis. In the absence of functional pVHL, uncontrolled angiogenesis can occur, contributing to tumor growth, invasion, and metastasis. Also, the VHL gene influences cell cycle progression and apoptosis, two fundamental processes in cellular homeostasis. pVHL has been found to interact with proteins involved in cell cycle regulation, such as cyclin-dependent kinase inhibitors (CDKIs) and components of the ubiquitin-proteasome system. These interactions result in the inhibition of cell cycle progression and the promotion of cell cycle arrest and apoptosis. Loss or inactivation of the VHL gene can disrupt these interactions, leading to uncontrolled cell proliferation and evasion of cell death, which are key hallmarks of cancer.

The tumor suppressor function of the VHL gene extends beyond its role in HIF regulation, angiogenesis, and cell cycle control. It interacts with various cellular pathways to maintain genomic stability and prevent tumor formation. For instance, pVHL has been found to interact with the mammalian target of rapamycin (mTOR) pathway, a key regulator of cell growth and metabolism. The disruption

of this interaction can contribute to dysregulated mTOR signaling, promoting tumorigenesis. Additionally, the VHL gene has been implicated in the regulation of the Wnt/β-catenin pathway and Notch signaling, which are involved in cell fate determination, cell differentiation, and tumorigenesis.

The VHL tumor suppressor gene operates through a multifaceted mechanism involving the regulation of HIF stability, control of angiogenesis and vascularization, impact on cell cycle progression and apoptosis, and interaction with other cellular pathways. The loss or inactivation of the VHL gene disrupts these mechanisms, leading to the development and progression of tumors. Understanding the intricate workings of the VHL gene and its associated pathways provides valuable insights into the underlying mechanisms of tumorigenesis and offers potential targets for therapeutic interventions.

VHL Gene Mutations and Cancer

VHL gene mutations can occur in different regions of the gene, leading to diverse functional consequences. The majority of VHL mutations are missense mutations, resulting in amino acid substitutions within the pVHL protein. These mutations can disrupt the structural integrity of the protein or interfere with its binding to other cellular components, compromising its tumor suppressor function. Other types of VHL gene mutations include nonsense mutations, frameshift mutations, and splice site mutations, which can lead to the production of nonfunctional or truncated pVHL protein. Hereditary VHL syndrome arises from germline mutations in one allele of the VHL gene, followed by the somatic loss or inactivation of the remaining wild-type allele in tumor cells. In contrast, sporadic VHL-related tumors result from the acquisition of two somatic mutations in the VHL gene within the affected tissue, leading to the complete loss of functional pVHL protein. Sporadic VHL-related tumors tend to occur later in life and are usually confined to a specific organ, whereas hereditary VHL syndrome is characterized by the development of multiple tumors in various organs, often at a younger age.

Renal cell carcinoma (RCC) is one of the most common tumors associated with VHL gene mutations. In VHL syndrome, RCC typically presents as clear cell carcinoma, which is characterized by the accumulation of glycogen and lipids within tumor cells. Loss of pVHL function leads to the dysregulation of HIFs, resulting in the upregulation of genes involved in angiogenesis, glucose metabolism, and cell proliferation. These molecular alterations contribute to the growth and progression of clear cell RCC. In addition to RCC, VHL gene mutations are associated with the development of other tumors, including central nervous system (CNS) hemangioblastomas, pheochromocytomas, and pancreatic neuroendocrine tumors. CNS hemangioblastomas are highly vascular tumors that can occur in the brain or spinal cord. Loss of pVHL function disrupts the regulation of angiogenesis, leading to the formation of these highly vascularized tumors.

Pheochromocytomas are neuroendocrine tumors that arise from the chromaffin cells of the adrenal medulla. They are characterized by the excessive production of catecholamines, which can result in hypertension, palpitations, and other symptoms. VHL gene mutations contribute to the development of pheochromocytomas by disrupting the regulation of angiogenesis and cellular proliferation in the adrenal medulla. Pancreatic neuroendocrine tumors (PNETs) are rare tumors that can occur in individuals with VHL syndrome. These tumors arise from the endocrine cells of the pancreas and can secrete various hormones. Loss of pVHL function disrupts cellular homeostasis in the pancreas, leading to the development of these neuroendocrine tumors.

The distinction between hereditary and sporadic VHL-related tumors is important for clinical management and genetic counseling. In hereditary VHL syndrome, individuals have a 50% chance of inheriting the mutated VHL gene from an affected parent. Regular surveillance and early detection of VHL-related tumors are crucial in individuals with VHL syndrome to optimize treatment outcomes. Genetic testing and counseling play a vital role in identifying individuals at risk for hereditary VHL syndrome and guiding appropriate screening measures for tumor surveillance. Genetic testing for VHL gene mutations is available and can be performed on individuals with a family history suggestive of VHL syndrome or those presenting with characteristic VHL-related tumors. Identifying the specific VHL gene mutation can provide valuable information for prognosis, as certain mutations have been associated with an increased risk of specific tumor types or a more aggressive disease course.

In terms of clinical management, the treatment of VHL-related tumors often involves a multidisciplinary approach tailored to the specific tumor type, location, and stage. Surgical interventions, such as nephrectomy for RCC or resection of CNS hemangioblastomas, remain the primary treatment options for localized tumors. However, the high recurrence rate and multifocality of some VHL-related tumors necessitate additional therapeutic modalities.

Diagnostic Methods for VHL Mutations

Accurate and timely diagnosis of Von Hippel-Lindau (VHL) syndrome and the identification of VHL gene

mutations are crucial for effective management and genetic counseling of individuals and families at risk. Various diagnostic methods are available to detect VHL mutations, including genetic testing, clinical evaluation, imaging techniques, and molecular analysis.

• Genetic Testing:

Genetic testing plays a central role in diagnosing VHL syndrome and identifying VHL gene mutations. It involves the analysis of DNA samples to detect mutations or deletions in the VHL gene. Genetic testing can be performed using various techniques, including polymerase chain reaction (PCR), Sanger sequencing, multiplex ligation-dependent probe amplification (MLPA), and next-generation sequencing (NGS) technologies. These methods allow for the detection of point mutations, small insertions or deletions, and large genomic rearrangements in the VHL gene.

Genetic testing is typically recommended for individuals with a family history of VHL syndrome or those presenting with characteristic VHL-related tumors, such as renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pheochromocytomas. Testing can be performed on blood samples or tumor tissue samples, depending on the specific clinical scenario. It is important to note that the interpretation of genetic testing results requires expertise in genetic counseling and a thorough understanding of VHL gene mutations and their implications.

• Clinical Evaluation:

Clinical evaluation is an integral part of the diagnostic process for VHL syndrome. It involves a comprehensive assessment of an individual's medical history, family history, and physical examination findings. Clinical features suggestive of VHL syndrome include the presence of characteristic VHL-related tumors in multiple organs, such as the retina, CNS, kidneys, adrenal glands, pancreas, and epididymis. Additionally, clinical evaluation may reveal associated manifestations, such as hypertension, renal dysfunction, or endolymphatic sac tumors.

The identification of specific clinical features associated with VHL syndrome can aid in the selection of appropriate individuals for genetic testing. Clinical criteria, such as those established by the International VHL Alliance, provide guidelines for diagnosing VHL syndrome based on the presence of specific tumor types and their distribution in affected individuals and families. These criteria consider both genetic testing results and clinical findings to ensure accurate diagnosis and appropriate management.

• Imaging Techniques:

Imaging techniques play a crucial role in the diagnosis and surveillance of VHL-related tumors. Various imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and ophthalmic examination, are employed to detect and monitor VHL-associated tumors in different organ systems.

CT and MRI scans are commonly used to evaluate RCC, CNS hemangioblastomas, pancreatic neuroendocrine tumors (PNETs), and other VHL-related tumors. These imaging techniques provide detailed anatomical information, allowing for the detection of tumors, assessment of their size and localization, and evaluation of disease progression. For example, abdominal CT or MRI scans can detect renal cysts or solid renal masses suggestive of RCC, while CNS imaging can identify the presence of CNS hemangioblastomas.

Ophthalmic examination, including indirect ophthalmoscopy and fundus photography, is essential for detecting retinal hemangioblastomas, a hallmark feature of VHL syndrome. Ophthalmic screening is typically performed regularly in individuals with VHL syndrome to detect and monitor the presence of retinal lesions.

Therapeutic Approaches for VHL-Related Tumors

The management of VHL-related tumors requires a multimodal approach that integrates surgery, targeted therapies, and emerging treatment modalities. Treatment decisions are guided by tumor characteristics, such as size, location, and presence of metastasis, as well as patient-specific factors. This section will discuss the therapeutic approaches used for VHL-related tumors, including surgical interventions, targeted therapies, radiotherapy, and emerging treatment strategies.

Surgical Interventions:

Surgery remains the mainstay of treatment for localized VHL-related tumors. The goal of surgical interventions is to achieve complete resection of tumors while preserving organ function whenever possible. The choice of surgical approach depends on the specific tumor type and its location. In renal cell carcinoma (RCC), partial nephrectomy or nephron-sparing surgery is preferred over radical nephrectomy, especially in patients with bilateral or multifocal tumors. This approach aims to preserve renal function while effectively removing the tumor mass. In cases where RCC is extensive or associated with significant renal impairment, radical nephrectomy may be necessary.

For central nervous system (CNS) hemangioblastomas, surgical resection is the primary treatment modality. The goal is to remove the tumor while preserving neurological function. In cases where the tumor is inaccessible or

associated with a high risk of complications, alternative approaches such as stereotactic radiosurgery or embolization may be considered. Similarly, surgical resection is the preferred treatment for pancreatic neuroendocrine tumors (PNETs) associated with VHL syndrome. Depending on the size and location of the tumor, options may include enucleation, distal pancreatectomy, or pancreaticoduodenectomy. Surgical interventions also play a role in managing other VHL-related tumors, such as pheochromocytomas, retinal hemangioblastomas, and endolymphatic sac tumors. In each case, the goal is to remove the tumor mass while preserving organ function and minimizing the risk of complications.

Targeted Therapies:

Targeted therapies have revolutionized the treatment landscape for VHL-related tumors. These therapies aim to exploit the underlying molecular abnormalities associated with VHL gene mutations, such as dysregulated angiogenesis and hypoxia-inducible factor (HIF) signaling. Several targeted agents have shown efficacy in VHL-related tumors, particularly in renal cell carcinoma (RCC). Anti-angiogenic agents, such as vascular endothelial growth factor receptor (VEGFR) inhibitors, have demonstrated clinical benefit in the treatment of VHL-related RCC. Drugs like sunitinib, pazopanib, and axitinib have been approved for advanced RCC and have shown favorable outcomes in patients with VHL-related tumors. These agents inhibit angiogenesis by targeting VEGFRs and disrupt the formation of new blood vessels, thereby reducing tumor vascularity and slowing tumor growth.

Another therapeutic approach targets the dysregulated HIF signaling pathway in VHL-related tumors. HIF-2α inhibitors, such as PT2385 and PT2977, have shown promising results in early-phase clinical trials for VHL-associated RCC. These agents selectively inhibit the aberrant HIF-2α signaling that occurs in the absence of functional pVHL, leading to tumor growth inhibition. Additionally, mTOR (mammalian target of rapamycin) inhibitors, including everolimus and temsirolimus, have demonstrated efficacy in VHL-related tumors. By inhibiting the mTOR pathway downstream of HIF, these agents disrupt the cellular processes involved in tumor growth and angiogenesis.

Radiotherapy:

Radiotherapy is employed in the management of VHL-related tumors when surgical resection is not feasible or in cases of tumor recurrence or residual disease after surgery. It involves the use of high-energy radiation beams to target and destroy tumor cells. Radiotherapy can be delivered externally (external beam radiotherapy) or internally (brachytherapy). In the case of CNS hemangioblastomas, stereotactic radiosurgery (SRS) is a non-invasive treatment option. SRS delivers highly focused radiation beams to precisely target the tumor, sparing the surrounding healthy brain tissue. This approach is particularly suitable for small to medium-sized tumors or those located in critical or difficult-to-access areas.

For metastatic or unresectable RCC, radiotherapy may be used to alleviate symptoms and provide local control. It can be employed as a palliative measure to relieve pain or manage symptoms related to bone metastases, brain metastases, or other sites of metastasis. Radiotherapy may also be utilized for the management of other VHL-related tumors, such as PNETs or retinal hemangioblastomas. The decision to use radiotherapy depends on the tumor size, location, and individual patient factors.

Conclusion:

Von Hippel-Lindau (VHL) syndrome is a rare genetic disorder characterized by the presence of various tumor types throughout the body. The discovery of the VHL tumor suppressor gene has significantly advanced our understanding of the molecular mechanisms underlying VHL-related tumorigenesis. The VHL gene encodes the pVHL protein, which plays a crucial role in regulating cellular processes such as angiogenesis, oxygen sensing, and tumor suppression. The identification of VHL gene mutations and their association with tumor development has provided valuable insights into the diagnosis, management, and genetic counseling of individuals affected by VHL syndrome. Genetic testing has become a cornerstone in the diagnosis of VHL syndrome, enabling the detection of pathogenic VHL gene mutations and facilitating early intervention and surveillance for tumor development. Clinical evaluation, including comprehensive physical examinations and imaging techniques, aids in the detection, monitoring, and characterization of VHL-related tumors.

The therapeutic management of VHL-related tumors involves a multimodal approach tailored to individual patients and tumor characteristics. Surgical interventions remain the primary treatment modality for localized tumors, aiming for complete tumor resection while preserving organ function. Targeted therapies, such as anti-angiogenic agents and HIF-2α inhibitors, have shown efficacy in advanced or metastatic tumors, offering new treatment options for patients with VHL-related renal cell carcinoma. Radiotherapy and emerging

treatment strategies, including immunotherapy and gene therapy, are being explored to further optimize treatment outcomes. The multidisciplinary approach involving healthcare professionals from various specialties, including genetics, oncology, radiology, and surgery, is essential for the comprehensive management of VHL syndrome. Collaboration among these disciplines allows for personalized treatment plans, incorporating genetic counseling, surveillance strategies, and therapeutic interventions to ensure the best possible outcomes for individuals and families affected by VHL syndrome.

Despite significant progress in the understanding and management of VHL-related tumors, challenges and unanswered questions remain. Further research is needed to elucidate the molecular mechanisms underlying VHL-related tumorigenesis, identify novel therapeutic targets, and develop more effective treatment strategies. Long-term follow-up studies are necessary to assess treatment outcomes, evaluate the potential benefits of emerging therapies, and improve the quality of life for individuals living with VHL syndrome. VHL syndrome represents a complex genetic disorder characterized by the development of multiple tumors in various organs. The identification of the VHL tumor suppressor gene has paved the way for improved diagnostic methods, targeted therapies, and personalized treatment approaches. Through continued research and collaboration, we can further advance our understanding of VHL syndrome and strive towards more effective interventions for individuals affected by this condition.

References

Kaelin Jr, W. G. (2002). Molecular basis of the VHL hereditary cancer syndrome. Nature Reviews Cancer, 2(9), 673-682.

Maher, E. R., Neumann, H. P., & Richard, S. (2011). Von Hippel-Lindau disease: a clinical and scientific review. European Journal of Human Genetics, 19(6), 617-623.

Lonser, R. R., Glenn, G. M., Walther, M., et al. (2003). von Hippel-Lindau disease. The Lancet, 361(9374), 2059-2067.

Choyke, P. L., Glenn, G. M., Walther, M., et al. (1995). von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology, 194(3), 629-642.

Kreuzer, M., Otto, T., von Deimling, A., et al. (2000). Genetic and functional characterization of the VHL-haplotype 1 in von Hippel-Lindau patients. Journal of Medical Genetics, 37(2), 107-111.

Choyke, P. L., Glenn, G. M., Walther, M., et al. (1992). The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients. American Journal of Roentgenology, 159(6), 1229-1234.

Jonasch, E., McCutcheon, I. E., Waguespack, S. G., et al. (2010). Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Annals of Oncology, 21(5), 98-103.

Rini, B. I., Bellmunt, J., Clancy, J., et al. (2009). Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. Journal of Clinical Oncology, 27(2), 374-381.

Jonasch, E., Donskov, F., Iliopoulos, O., et al. (2021). Phase III Randomized Study of Pemigatinib, a FGFR Inhibitor, Versus Everolimus in Patients With Advanced or Metastatic Urothelial Carcinoma: The FIGHT-211 Study. Journal of Clinical Oncology, 39(18), 1911-1920.

Choueiri, T. K., Plimack, E. R., Arkenau, H. T., et al. (2017). Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer. Journal of Clinical Oncology, 35(23), 2993-3001.